Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease

International Journal of Cardiology

Volumn 113, Issue 2, 2006, Pages 167-173

  Johnston, Nina ^a   Jernberg, Tomas ^b   Lagerqvist, Bo ^b   Siegbahn, Agneta ^b   Wallentin, Lars ^b  

^a Department of Medical Sciences   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiac event; Coronary artery disease; Oxidized low density lipoprotein

Indexed keywords

OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK;

AGED; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; SWEDEN;

EID: 33750460629     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2005.11.006     Document Type: Article

References (34)

1. Bertrand M.E., Simoons M.L., Fox K.A., et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 23 (2002) 1809-1840
2. Berliner J.A., Navab M., Fogelman A.M., et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91 (1995) 2488-2496
3. Quinn M.T., Parthasarathy S., Fong L.G., and Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A 84 (1987) 2995-2998
4. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witzum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320 (1989) 915-924
5. Li D., Liu L., Chen H., Sawamura T., Ranganathan S., and Mehta J.L. LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 107 (2003) 612-617
6. Relou I.A., Hackeng C.M., Akkerman J.W., and Malle E. Low-density lipoprotein and its effect on human blood platelets. Cell Mol Life Sci 60 (2003) 961-971
7. Kugiyama K., Sakamoto T., Misumi I., et al. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res 73 (1993) 335-343
8. Holvoet P., Mertens A., Verhamme P., et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21 (2001) 844-848
9. Toshima S., Hasegawa A., Kurabayashi M., et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 20 (2000) 2243-2247
10. Suzuki T., Kohno H., Hasegawa A., et al. Diagnostic implications of circulating oxidized low density lipoprotein levels as a biochemical risk marker of coronary artery disease. Clin Biochem 35 (2002) 347-353
11. Holvoet P., Vanhaecke J., Janseens S., Van de Werf F., and Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98 (1998) 1487-1494
12. Ehara S., Ueda M., Naruko T., et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103 (2001) 1955-1960
13. Nordin Fredrikson G., Hedblad B., Berglund G., and Nilsson J. Plasma oxidized LDL: a predictor for acute myocardial infarction?. J Intern Med 253 (2003) 425-429
14. Holvoet P., Kritchevsky S.B., Tracy R.P., et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 53 (2004) 1068-1073
15. Meisinger C., Baumert J., Kusheyinova N., Loewel H., and Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 112 (2005) 651-657
16. Shimadam K., Mokuno H., Matsunaga E., et al. Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis 174 (2004) 343-347
17. Tsimikas S., Witztum J.L., Miller E.R., et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 110 (2004) 1406-1412
18. Johnston N., Jernberg T., Lindahl B., et al. Biochemical indicators of cardiac and renal function in a healthy elderly population. Clin Biochem 37 (2004) 210-216
19. FRISC-2 Investigators. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet 354 (1999) 708-715
20. Wallentin L. Non-ST-elevation acute coronary syndrome: fuel for the invasive strategy. Lancet 360 (2002) 738-739
21. Lagerqvist B., Husted S., Konty F., Stahle E., and Swahn E. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. J Am Coll Cardiol 40 (2002) 1902-1914
22. Lagerqvist B., Diderholm E., Lindahl B., et al. FRISC score for selection of patients for an early invasive treatment strategy in unstable coronary artery disease. Heart 91 (2005) 1047-1052
23. Lindahl B., Diderholm E., Lagerqvist B., Venge P., Wallentin L., and FRISC II(Fast Revascularisation during InStability in CAD) investigators. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 38 (2001) 979-986
24. Casscells W., Naghavi M., and Willerson J.T. Vulnerable atherosclerotic plaque: a multifocal disease. Circulation 107 (2003) 2072-2075
25. Ehara S., Ueda M., Naruko T., et al. Pathophysiological role of oxidized low-density lipoprotein in plaque instability in coronary artery diseases. J Diabetes Complications 16 (2002) 60-64
26. Ndrepepa G., Braun S., von Beckerath N., et al. Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease. Clin Chim Acta (2005 (Jun. 30)) [Electronic publication ahead of print]
27. Anselmi M., Garbin U., Agostino P., et al. Plasma levels of oxidized-low-density lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaques. Atherosclerosis (2005 (Jul. 2)) [Electronic publication ahead of print]
28. Harats D., Ben-Naim M., Dabach Y., et al. Cigarette smoking renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages. Atherosclerosis 9 (1989) 245-252
29. Frostegard J., Wu R., Lemne C., Thulin T., Witztum J.L., and de Faire U. Circulating oxidized low-density lipoprotein is increased in hypertension. Clin Sci (Lond) 105 (2003) 615-620
30. Mertens A., and Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 15 (2001) 2073-2084
31. Itabe H. Oxidized low-density lipoproteins: what is understood and what remains to be clarified. Biol Pharm Bull 26 (2003) 1-9
32. Berliner J.A., and Watson A.D. A role for oxidized phospholipids in atherosclerosis. N Engl J Med 353 (2005) 9-11
33. Pietila K., Harmoinen A., Poyhonen L., and Ruosteenoja R. C-reactive protein in subendocardial and transmural myocardial infarcts. Clin Chem 32 (1986) 1596-1597
34. Tsutsui T., Tsutamoto T., Wada A., et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol 39 (2002) 957-962